Development of Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
This is a blood serum collection study at Stanford University for patients with cancer at a
variety of disease sites. The purpose of this study is to collect and store blood serum
from patients before, during, and after anti-cancer therapy to find new biomarkers that
signal disease or response to anti-cancer therapy. The collection and analysis of these
biomarkers may lead to improved diagnostic and treatment therapies for certain cancers in
the future. We are also interested in collecting blood serum from healthy individuals such
as the spouses, relatives, and friends of cancer patients to obtain healthy controls for
comparison
Observational
Observational Model: Cohort, Time Perspective: Prospective
Survival analysis and response to anti-cancer therapy
At each follow-up (3 months, 6 months, 1 year; at discretion of MD) 2- Safety Issue?- No
No
Albert Koong
Principal Investigator
Stanford University
United States: Institutional Review Board
VAR0006
NCT00349830
January 2002
Name | Location |
---|---|
Stanford University School of Medicine | Stanford, California 94305-5317 |